Clinical trials: Treatment Free Remission
CML
A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation
To evaluate molecular relapse free rates 6 months after stopping nilotinib therapy in patients who achieve MR4.5
- Trial name
- ENESTgoal (NCT01744665)
- Testing
- nilotinib
- Where
- 54 sites in United States
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Folate, CML
FLOR3 Gene Polymorphism in Predicting Outcomes of Tyrosine Kinase Inhibitor（TKI）Stopping in Chronic Myeloid Leukemia
For patients with chronic myeloid leukemia in chronic phase (CML-CP) who have achieved a stable deep molecular response (DMR) using BCR-ABL1 tyrosine kinase inhibitors (TKIs), treatment-free remission (TFR) following TKI…
- Conditions
- Folate, CML, Treatment-free Remission
- Trial name
- NTU-CML-001 (NCT05152537)
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Affiliated Hospital of Nantong University
Celiac Disease
Safety of Prolonged Administration of Triticum Monococcum in Celiac Disease
Preliminary studies on safety profile of Triticum Monococcum (Tm, a variety of Ancient Wheat) have provided conflicting results with some in vitro and ex vivo studies consistent with non toxicity and other suggestive of toxicity.
- Trial name
- NCT02220166
- Testing
- Triticum monococcum
- Where
- Italy
- Volunteers
- 8 people
- Sponsor
- Università degli Studi di Brescia
Crohn's Disease
A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy
Phase IV Design : Prospective, open-label, randomized three-arms study Main Inclusion criteria Luminal Crohn's disease patients with steroid free remission for at least 6 months and a combination therapy with infliximab and…
- Trial name
- SPARE (NCT02177071)
- Testing
- INFLIXIMAB, AZATHIOPRINE, MERCAPTOPURINE
- Where
- 27 sites in Australia, Belgium and 1 more
- Volunteers
- 211 people
- Sponsor
- Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
Chronic Myeloid Leukemia, Treatment Free Remission
To Study the Impact of Stopping Therapy in Patients of CML With Molecular Remission
Patients with chronic myeloid leukemia (CML) are conventionally put on life long therapy with tyrosine kinase inhibitor drugs (Imatinib mesylate in India).
- Trial name
- NCT03062436
- Testing
- Stopping the standard drug therpy, Quantitative bcrabl recording every month for first 6 months
- Where
- India
- Volunteers
- 27 people
- Sponsor
- Command Hospital, India
Philadelphia Chromosome Positive (PH+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.
This study aimed to assess the optimal duration of nilotinib 300 mg twice daily (BID) consolidation treatment in patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML), in order that patients remained…
- Trial name
- ENESTPath (NCT01743989)
- Testing
- Nilotinib
- Where
- 208 sites in Austria, Belgium and 19 more
- Volunteers
- 620 people
- Sponsor
- Novartis Pharmaceuticals
CML (Chronic Myelogenous Leukemia)
Ropeginterferon for Treatment Free Remission
Ropeginterferon is a long-acting next-generation mono-pegylated interferon alfa-2b consisting of one isoform produced by PharmaEssentia Co.
- Trial name
- ROPEG (NCT07105319)
- Testing
- Ropeginterferon
- Where
- South Korea
- Volunteers
- 65 people
- Sponsor
- Dong-Wook Kim
Ulcerative Colitis
Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis
There are fewer therapeutic options for patients with active ulcerative colitis (UC) compared to patients with active Crohn's disease (CD) and the investigators are facing a persistent unmet need for additional effective and…
- Trial name
- Merit-UC (NCT01393405)
- Testing
- Methotrexate
- Where
- 31 sites in United States
- Volunteers
- 179 people
- Sponsor
- University of North Carolina, Chapel Hill
Chronic Myeloid Leukemia
A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia
This study is constituted of two stage: Treatment-Free Remission 1 (TFR1) stage and Treatment-Free Remission 2 (TFR2) stage. The purpose of the TFR1 stage is to assess the effect of nilotinib reduced to half the standard dose for…
- Trial name
- DANTE (NCT03874858)
- Testing
- Nilotinib, Asciminib
- Where
- 26 sites in Italy
- Volunteers
- 135 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
The study is designed to compare the efficacy of asciminib 80 mg QD versus Investigator selected Tyrosine Kinase Inhibitor (TKI) for the treatment of newly diagnosed, previously untreated patients with Ph+ CML-CP.
- Trial name
- NCT04971226
- Testing
- Imatinib, Nilotinib, Bosutinib
- Where
- 110 sites in United States, Australia and 27 more
- Volunteers
- 405 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia
This phase II trial studies how stopping tyrosine kinase inhibitors will affect treatment-free remission in patients with chronic myeloid leukemia in chronic phase.
- Trial name
- NCT03817398
- Testing
- Biospecimen Collection, Drug Withdrawn, Quality-of-Life Assessment
- Where
- 173 sites in United States, Australia and 2 more
- Volunteers
- 110 people
- Sponsor
- Children's Oncology Group
Chronic Myeloid Leukemia, BCR/ABL-Positive
Follow-up Study on Chronic Myeloid Leukemia Patients Achieving Treatment-free Remission
In recent years, the goal of stopping drug therapy, also known as treatment-free remission (TFR), is emerging as one of the management goals of chronic myeloid leukemia (CML) therapy.
- Trial name
- NCT05439889
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
Chronic Myeloid Leukemia, Treatment-free Remission
Treatment Free Remission (TFR) in CML Patients （CML-CP）Study
Improving the quality of life and achieving Treatment-Free Remission(TFR) is a long-term goal of treatment in CML-CP patients, and deep molecular response (DMR) is necessary to achieve TFR.
- Trial name
- NCT05440747
- Testing
- TFR(Treatment-Free Remission)
- Volunteers
- 203 people
- Sponsor
- Guangdong Provincial People's Hospital
Chronic Myeloid Leukemia
Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia
Ponatinib has shown to induce deeper molecular responses compared with imatinib. Therefore, ponatinib treatment could increase the proportion of patients who could discontinue treatment successfully.
- Trial name
- NCT04043676
- Testing
- Ponatinib
- Where
- 9 sites in Spain
- Volunteers
- 40 people
- Sponsor
- Fundación Teófilo Hernando, Spain
CML (Chronic Myelogenous Leukemia)
Phase I Trial of Vididencel in CML-CP Patients With MRD Under TKI Treatment
The main purpose of the trial is to evaluate the safety and potential side effects of cell therapy vididencel in Chronic Myeloid Leukemia (CML) participants with measurable residual disease (MRD) unable to stop treatment with…
- Trial name
- NCT07651878
- Testing
- vididencel
- Where
- Norway
- Volunteers
- 24 people
- Sponsor
- Mendus
Bone Sarcoma, Osteosarcoma
Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients
This is a multicenter phase II study concerning patients with high-grade bone sarcoma (HGBS) without complete remission after standard treatment at diagnosis or at relapse.
- Trial name
- REGOMAIN (NCT04698785)
- Testing
- Treatment by regorafenib and best supportive care
- Where
- 16 sites in France
- Volunteers
- 36 people
- Sponsor
- Centre Leon Berard
Leukemia, Chronic Myeloid
Study of Imatinib Discontinuation in Chronic Myeloid Leukemia With Deep Molecular Response
The purpose of this study is to evaluate treatment-free remission after imatinib discontinuation in patients with chronic myeloid leukemia with deep molecular response.
- Trial name
- EDI-PIO (NCT02852486)
- Testing
- Pioglitazone 30 Mg Oral Tablet, imatinib discontinuation
- Where
- Brazil
- Volunteers
- 31 people
- Sponsor
- University of Campinas, Brazil
Crohn's Disease
An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease
The purpose of this study is to see if Epanova™ is able to maintain the symptomatic remission in subjects with Crohn's Disease who are responding to steroid induction therapy.
- Trial name
- NCT00074542
- Testing
- Epanova™ (Omega-3 Free Fatty Acids)
- Where
- 31 sites in United States, Canada
- Volunteers
- 364 people
- Sponsor
- Tillotts Pharma AG
Chronic Lymphocytic Leukemia (CLL)
A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent).
The purpose of this open-label, single-arm study was to evaluate the impact of venetoclax on the quality of life of participants including those with with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL; a type of…
- Trial name
- VENICE II (NCT02980731)
- Testing
- Venetoclax
- Where
- 33 sites in Argentina, Australia and 8 more
- Volunteers
- 210 people
- Sponsor
- AbbVie
Leukemia, Myeloid, Acute
Study of Vosaroxin and Cytarabine for the Treatment of Adults 60 Years of Age or Older With Previously Untreated AML
This is a pilot efficacy assessment clinical trial of vosaroxin and cytarabine for the treatment of adults 60 years of age or older with previously untreated acute myeloid leukemia.
- Trial name
- NCT02485353
- Testing
- Vosaroxin and Cytarabine
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Hamid Sayar